RSOH is a leading player in the North Sea market and is a direct competitor to IQARUS’s UK operations, offering medical assessments, sickness absence reviews, travel health and health surveillance.
Tim Mitchell, CEO of IQARUS, said that the acquisition would strengthen IQARUS’ position in the UK market and provide enhanced service delivery to an increasingly diversified customer portfolio.
Robert Devonshire, Investment Director at MML, comments:
“RSOH significantly bolsters IQARUS’s UK operations and continues its strong momentum in executing strategic acquisitions within a fragmented market.”
MML invested into IQARUS in October 2015 from it’s recently raised €438m Fund VI.
IQARUS was acquired as a platform from which to develop an international provider of remote healthcare solutions. RSOH is the third acquisition that MML has supported this year alongside significant investment in technology enabled medical solutions.